Arrowhead Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended June 30, 2023; filed August 7, 2023. Arrowhead develops RNA interference (RNAi) medicines, with a mix of wholly owned and partnered programs. The financial statements are unaudited.
Financial performance and position
- Revenue: Third-quarter revenue was $15.8 million, down 51.2% from $32.4 million a year earlier. Nine-month revenue was $224.6 million, up 6.1% from $211.7 million. Revenue primarily reflects collaboration and license agreements, including Takeda, GSK, Horizon, and Amgen; it is not product-sales revenue.
- Losses: Third-quarter operating loss was $102.7 million versus $72.9 million; net loss attributable to Arrowhead was $102.9 million, or $0.96 per diluted share, versus $72.0 million, or $0.68 per share. For nine months, operating loss was $96.7 million versus $94.7 million; net loss attributable to Arrowhead was $95.6 million, or $0.90 per diluted share, versus $90.6 million, or $0.86 per share.
- Expenses: Third-quarter R&D expense rose 31% to $94.8 million, reflecting pipeline advancement, clinical-trial and manufacturing costs, discovery activity, and headcount. Nine-month R&D expense rose 18% to $253.3 million. G&A expense declined 28% in the quarter and 26% for nine months, largely because of lower recognized stock-based compensation, including a reversal related to a performance award.
- Margins and cash flow: The filing does not present gross profit or gross margin; those measures are not meaningful in the same way for this collaboration-revenue business. Nine-month operating cash use was $128.6 million versus $67.4 million; investing cash use was $126.7 million versus $41.9 million; financing provided $252.9 million versus $64.3 million. The period-end cash decrease was $2.4 million.
- Liquidity: At June 30, cash, cash equivalents and restricted cash totaled $105.3 million; short-term investments were $346.4 million and long-term investments $42.8 million. Combined, these totaled approximately $494.5 million. Current assets were $470.2 million and current liabilities $70.2 million. Management expects available resources to fund operations for at least 12 months.
- Debt-like obligation and capital spending: The balance sheet included a $263.1 million liability related to the sale of future Olpasiran royalties to Royalty Pharma; the transaction generated $250 million upfront and is accounted for as debt. Related non-cash interest expense was $13.1 million for nine months. Property and equipment, net, rose to $231.4 million from $110.3 million. The company had spent $102.7 million on its Verona, Wisconsin facilities and expected to spend another $160–$180 million to complete them.
Material changes and notable developments
- Takeda’s revised expected timing for Phase 2 Fazirsiran study visits shortened Arrowhead’s performance period and accelerated $61.4 million of revenue in both the quarter and nine-month period. The estimate change contributed $0.58 per share, diluted, for each reported period.
- Collaboration milestones included $40 million from Takeda after the first patient was dosed in the Phase 3 REDWOOD study and $30 million from GSK after the first patient entered its Phase 2b trial. The company also reported earlier-period milestone payments of $15 million from Horizon and $25 million from Amgen.
- Janssen terminated its research collaboration, effective April 7, 2023; Arrowhead regained full rights to ARO-PNPLA3 and is developing it independently.
- The company completed enrollment in the Phase 3 PALISADE trial of ARO-APOC3 for familial chylomicronemia syndrome. FDA Fast Track designation was granted for that program.
- Management reported Fazirsiran Phase 2 results including fibrosis improvement in 50% of treated patients versus 38% on placebo, and interim ARO-ANG3 and ARO-C3 findings. ARO-SOD1’s clinical trial application was filed in June 2023. These remain investigational programs; reported findings do not establish approval or commercial success.
Outlook, risks, and contingencies
- Management expects R&D costs to continue increasing as the pipeline expands and advances into later-stage trials; G&A costs are also expected to rise, excluding the described stock-compensation effect. The filing gives no specific revenue, earnings, or cash-burn guidance.
- Arrowhead is eligible for up to $3.4 billion in aggregate development, regulatory, and sales milestones under licensing and collaboration agreements, plus potential royalties; timing and receipt depend on program progress and agreement terms.
- Royalty Pharma may pay up to an additional $160 million under specified Olpasiran-related milestones. In exchange, it receives royalties otherwise payable to Arrowhead by Amgen; Arrowhead retains eligibility for certain milestone payments.
- Verona facility reimbursements of up to $16 million depend on future tax revenues, and up to $2.5 million in Wisconsin tax credits are expected. These amounts are not assured. The company also has an unused at-the-market equity sales authorization of up to $250 million, which could dilute shareholders if shares are sold.
- The filing reported no contingent liabilities recorded and no material changes to the risk factors in the prior Form 10-K. Key risks include clinical and regulatory uncertainty, reliance on partners and milestone-based revenue, ongoing cash needs, and facility investment commitments. Management stated disclosure controls were effective.
Important facts for investors to verify
- How much of reported revenue and future revenue depends on Takeda’s accelerated recognition estimate, milestones, and other partner arrangements.
- Whether clinical trial progress and results support the anticipated timelines and potential for approval, particularly for Fazirsiran, ARO-APOC3, ARO-ANG3, and ARO-C3.
- Whether operating cash use, rising R&D spending, and Verona construction costs remain consistent with management’s at-least-12-month liquidity assessment.
- The repayment trajectory and effective interest cost of the Royalty Pharma liability, and the royalties and milestones Arrowhead retains or has assigned.
- Potential dilution from equity compensation, the expanded authorized share count, and any future use of the $250 million ATM facility.